 WALTHAM, Mass., March 02, 2022 GLOBE NEWSWIRE -- TScan Therapeutics, Inc. Nasdaq: TCRX, a biopharmaceutical company focused on the development of T cell receptor TCR engineered T cell therapies TCR-T for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: 